Drug Type Small molecule drug |
Synonyms 2-sulfanilamidopyrimidine, 2-sulfanilylaminopyrimidine, 4-amino-N-2-pyrimidinylbenzenesulfonamide + [18] |
Target |
Mechanism bacterial DHPS inhibitors(Bacterial dihydropteroate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (11 Aug 1941), |
RegulationOrphan Drug (JP) |
Molecular FormulaC10H10N4O2S |
InChIKeySEEPANYCNGTZFQ-UHFFFAOYSA-N |
CAS Registry68-35-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00587 | Sulfadiazine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bacterial Infections | CA | 31 Dec 1957 |
Not Applicable | - | fhnezuvyvq(yjzalstmoh) = Our patient developed severe but reversible post-obstructive AKI secondary to high-dose sulfadiazine-induced nephrolithiasis wizlwdszpx (bjmfgfgzhc ) View more | Negative | 19 Oct 2020 | |||
Phase 2/3 | 34 | silver sulfadiazine cream+Epidermal growth factor (Epidermal Growth Factor With Silver Sulfadiazine Cream) | tyjeehcqbk(gubwjgynxe) = kvzpdlguov amlihxnpyy (evdlhxvten, tgkkhwzrpq - txceolghdf) View more | - | 09 Aug 2012 | ||
(Silver Zinc Sulfadiazine Cream) | tyjeehcqbk(gubwjgynxe) = gbkpdnatkq amlihxnpyy (evdlhxvten, whwlkigzqv - rsjnkevqmr) View more |